Danbee Kang, Ka Ryeong Bae, Yeojin Ahn, Nayeon Kim, Seok Jin Nam, Jeong Eon Lee, Se Kyung Lee, Young Mog Shim, Dong Hyun Sinn, Seung Yeop Oh, Mison Chun, Jaesung Heo, Juhee Cho
Cancer Res Treat. 2023;55(2):419-428. Published online November 8, 2022
Purpose We developed a comprehensive return to work (RTW) intervention covering physical, psycho-social and practical issues for patients newly diagnosed and evaluated its efficacy in terms of RTW.
Materials and Methods A multi-center randomized controlled trial was done to evaluate the efficacy of the intervention conducted at two university-based cancer centers in Korea. The intervention program comprised educational material at diagnosis, a face-to-face educational session at completion of active treatment, and three individualized telephone counseling sessions. The control group received other education at enrollment.
Results At 1-month post-intervention (T2), the intervention group was more likely to be working compared to the control group after controlling working status at diagnosis (65.4% vs. 55.9%, p=0.037). Among patients who did not work at baseline, the intervention group was 1.99-times more likely to be working at T2. The mean of knowledge score was higher in the intervention group compared to the control group (7.4 vs. 6.8, p=0.029). At the 1-year follow-up, the intervention group was 65% (95% confidence interval, 0.78 to 3.48) more likely to have higher odds for having work.
Conclusion The intervention improved work-related knowledge and was effective in facilitating cancer patients’ RTW.
Citations
Citations to this article as recorded by
Supporting Life Adjustment in Patients With Lung Cancer Through a Comprehensive Care Program: Protocol for a Controlled Before-and-After Trial Wonyoung Jung, Alice Ahn, Genehee Lee, Sunga Kong, Danbee Kang, Dongok Lee, Tae Eun Kim, Young Mog Shim, Hong Kwan Kim, Jongho Cho, Juhee Cho, Dong Wook Shin JMIR Research Protocols.2024; 13: e54707. CrossRef
A visualized and bibliometric analysis of cancer vocational rehabilitation research using CiteSpace Zebing Luo, Xuejia Liu, Chujun Chen Work.2024; : 1. CrossRef
Psychosocial Adjustment Experiences Among Nasopharyngeal Carcinoma Survivors Jie Jiang, Ming-Hui Yan, Yu-Ying Fan, Jun-E Zhang Cancer Nursing.2023;[Epub] CrossRef
Purpose
Recently, the 8th edition staging system of the American Joint Committee on Cancer (AJCC) for hepatocellular carcinoma (HCC) was released, including a change in T category. We aimed to validate the new AJCC system.
Materials and Methods
The predictive value of the new AJCC was validated in comparison to the previous edition, in a total 1,008 patients who underwent curative resection for HCC as initial treatment.
Results
The 2-year area under the curve values for recurrence-free survival (RFS) and overall survival (OS) were comparable in the 7th and 8th editions. Stage migration was observed in 63 patients (6.3%); from T2 to T1a for 44 patients and from T3 to T4 for 19 patients. The RFS and OS were not different between T1a and T1b in the 8th edition. For solitary tumors ≤ 2 cm, those with microvascular invasion had lower RFS and OS values than those without although they were all classified as T1a in the 8th edition. Tumors involving a major branch of the portal or hepatic vein (T4 by the 8th edition and T3b by the 7th edition) had shorter RFS and OS than multifocal tumors, at least one of which was > 5 cm (T3 by the 8th edition and T3a by the 7th edition).
Conclusion
The AJCC 8th edition staging system for HCC showed comparable predictive performance to the 7th edition. It is desirable in a future revision to consider sub-stratification of solitary tumors ≤ 2 cm (T1a) depending on the presence of vascular invasion, which is not included in the 8th edition.
Citations
Citations to this article as recorded by
Improving Adherence of Young Male Patients with HBV Infection to the Regular Follow-Up via Mobile Healthcare Platform Might Be Cost-Effective to Decrease the Morbidity of Advanced Liver Cancer Hao Liang, Min Yang, Dan Luo, Ya-Kun Wu Patient Preference and Adherence.2024; Volume 18: 2581. CrossRef
Prognostic impact of tumor size on isolated hepatocellular carcinoma without vascular invasion may have age variance Yi Zhang, Jun-Gang Zhang, Wei Yu, Lei Liang, Chun Wu, Cheng-Wu Zhang, Ya-Ming Xie, Dong-Sheng Huang, Ying Shi Frontiers in Surgery.2023;[Epub] CrossRef
Advances in post-operative prognostic models for hepatocellular carcinoma Ziqin He, Xiaomin She, Ziyu Liu, Xing Gao, Lu Lu, Julu Huang, Cheng Lu, Yan Lin, Rong Liang, Jiazhou Ye Journal of Zhejiang University-SCIENCE B.2023; 24(3): 191. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Overall survival among patients who undergo resection does not differ significantly between T1a and T1b hepatocellular carcinoma based on the 8th American Joint Commission on Cancer Yueh-Wei Liu, Wei-Feng Li, Fang-Ying Kuo, Hock-Liew Eng, Chih-Chi Wang, Chih-Che Lin, Chee-Chien Yong, Yi-Hao Yen Langenbeck's Archives of Surgery.2023;[Epub] CrossRef
Perfusion parameters of triphasic computed tomography hold preoperative prediction value for microvascular invasion in hepatocellular carcinoma Li Zhang, Guodong Pang, Jing Zhang, Zhenguo Yuan Scientific Reports.2023;[Epub] CrossRef
AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma Diwakar Suresh, Akshatha N. Srinivas, Akila Prashant, Suchitha Satish, Prashant Vishwanath, Suma M. Nataraj, Srinivas V. Koduru, Prasanna K. Santhekadur, Divya P. Kumar Frontiers in Oncology.2023;[Epub] CrossRef
ESR1 Regulates the Obesity- and Metabolism-Differential Gene MMAA to Inhibit the Occurrence and Development of Hepatocellular Carcinoma Yiyin Zhang, Jiaxi Cheng, Cheng Zhong, Qiming Xia, Yirun Li, Peng Chen, Xiaoxiao Fan, Qijiang Mao, Hui Lin, Defei Hong Frontiers in Oncology.2022;[Epub] CrossRef
Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients With Microscopic Portal Vein Invasion Yiwen Qiu, Yi Yang, Tao Wang, Shu Shen, Wentao Wang Frontiers in Oncology.2022;[Epub] CrossRef
Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma—A Multicentre Experience Zehao Zheng, Renguo Guan, Yiping Zou, Zhixiang Jian, Ye Lin, Rongping Guo, Haosheng Jin Journal of Inflammation Research.2022; Volume 15: 5089. CrossRef
CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma Wang Zhang, Yipeng Wan, Yue Zhang, Qi Liu, Xuan Zhu Cancer Management and Research.2022; Volume 14: 2691. CrossRef
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology.2022; 28(4): 583. CrossRef
Revisiting Surgical Strategies for Hepatocellular Carcinoma With Microvascular Invasion Er-lei Zhang, Qi Cheng, Zhi-yong Huang, Wei Dong Frontiers in Oncology.2021;[Epub] CrossRef
Two-Trait Predictor of Venous Invasion on Contrast-Enhanced CT as a Preoperative Predictor of Outcomes for Early-Stage Hepatocellular Carcinoma After Hepatectomy Xinming Li, Xuchang Zhang, Zhipeng Li, Chuanmiao Xie, Shuping Qin, Meng Yan, Qiying Ke, Xuan Jin, Ting Lin, Muyao Zhou, Wen Liang, Zhendong Qi, Zhijun Geng, Xianyue Quan Frontiers in Oncology.2021;[Epub] CrossRef
Construction and Validation of an Immune Cell Signature Score to Evaluate Prognosis and Therapeutic Efficacy in Hepatocellular Carcinoma Linfeng Xu, Xingxing Jian, Zhenhao Liu, Jingjing Zhao, Siwen Zhang, Yong Lin, Lu Xie Frontiers in Genetics.2021;[Epub] CrossRef
Up-to-date Knowledge on the Pathological Diagnosis of Hepatocellular Carcinoma Ji Hae Nahm, Young Nyun Park The Korean Journal of Gastroenterology.2021; 78(5): 268. CrossRef